Hematology

OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.

Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.

The approval follows the ECHELON-3 study, which enrolled adults with relapsed or refractory large B-cell lymphoma.

The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.

Circulating lactate is increased in patients with myelofibrosis and corresponds with the remodeling of lactate export channel monocarboxylate transporter 4, suggesting a link with fibrosis establishment.

J Ryan Shaw, PharmD, BCPS, BCOP, CPP, discusses the value of the ASTCT and CIBMTR Tandem Meeting 2025 as a platform for multidisciplinary collaboration, cutting-edge education, and advancing pharmacy practice in transplant and cellular therapy.

Catriona Jamieson, MD, PhD, discusses the role of stress-activated base editors like ADAR1p150 and APOBEC enzymes in cancer progression and highlights innovative approaches to halt these processes and improve therapeutic outcomes.

The quadruple treatment was active and safe as initial therapy for older patients with transplant-ineligible multiple myeloma.

γδ T cells are emerging as a transformative immunotherapy approach in oncology, offering unique mechanisms for targeting hematologic and solid tumors, with clinical trials demonstrating promising survival outcomes and durable immune responses.

Myelofibrosis patients with CALR mutations have lower responses to symptoms and higher rates of anemia after 6 months of therapy with ruxolitinib.

Diagnosing anemia, a serious and common complication of patients with myelofibrosis, could be made easier with the use of red cell distribution width assessment.

Leukemia biology may predict patterns of blinatumomab failure after initial response.

Data indicates fedratinib’s role as an effective second-line treatment in patients with myelofibrosis who have been previously treated with a JAK inhibitor, such as ruxolitinib, though more research is necessary.

Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival.

Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.

Patients with myelofibrosis have a higher likelihood of having a cardiovascular risk factor when compared with essential thrombocythemia or polycythemia vera.

The FDA approved treosulfan, in combination with fludarabine, for patients 1 year of age and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

A phase 2 trial investigates MRD detection and therapy advancements.

The international cohort study evaluated the safety, efficacy of BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel.

Investigators assessed fixed-duration venetoclax plus acalabrutinib with or without obinutuzumab vs chemoimmunotherapy.

The closure of Baxter’s North Cove facility has significantly impacted existing IV fluid shortages into 2025.

Presentations detail clinical trial results and drugs in the pipeline.

Admissions to the hospital for fever were reduced in pediatric patients with medium-risk ALL receiving intravenous immunoglobulin, a potentially useful finding to help prevent infections in vulnerable patients.

These drugs are set to revolutionize their respective disease states in 2025.

Acalabrutinib with bendamustine and rituximab shows efficacy in patients with untreated mantel cell lymphoma by increasing progression-free survival in the ECHO trial.

The combination yields promising results but was associated with high incidence of toxicity and infection.

This association was also observed in siblings of children with autism spectrum disorder.

The analysis shows patients achieved deep and durable responses despite being ineligible for the CARTITUDE-1 trial.

Patients with relapsed, refractory disease achieved deep, durable responses with equecabtagene autoleucel.

Constantine Tam, MD, discusses zanubrutinib's efficacy in CLL/SLL, emphasizing its durability, high response rates, safety considerations, and evolving therapeutic potential in combination with other agents.